Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

Division of Hematology/Oncology, University of North Carolina at Chapel Hill, CB no. 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27599-7305, USA.
Blood (Impact Factor: 9.78). 04/2008; 111(8):3991-7. DOI: 10.1182/blood-2007-08-110098
Source: PubMed

ABSTRACT Senicapoc, a novel Gardos channel inhibitor, limits solute and water loss, thereby preserving sickle red blood cell (RBC) hydration. Because hemoglobin S polymerization is profoundly influenced by intracellular hemoglobin concentration, senicapoc could improve sickle RBC survival. In a 12-week, multicenter, phase 2, randomized, double-blind, dose-finding study, we evaluated senicapoc's safety and its effect on hemoglobin level and markers of RBC hemolysis in sickle cell anemia patients. The patients were randomized into 3 treatment arms: placebo; low-dose (6 mg/day) senicapoc; and high-dose (10 mg/day) senicapoc. For the primary efficacy end point (change in hemoglobin level from baseline), the mean response to high-dose senicapoc treatment exceeded placebo (6.8 g/L [0.68 g/dL] vs 0.1 g/L [0.01 g/dL], P < .001). Treatment with high-dose senicapoc also produced significant decreases in such secondary end points as percentage of dense RBCs (-2.41 vs -0.08, P < .001); reticulocytes (-4.12 vs -0.46, P < .001); lactate dehydrogenase (-121 U/L vs -15 U/L, P = .002); and indirect bilirubin (-1.18 mg/dL vs 0.12 mg/dL, P < .001). Finally, senicapoc was safe and well tolerated. The increased hemoglobin concentration and concomitant decrease in the total number of reticulocytes and various markers of RBC destruction following senicapoc administration suggests a possible increase in the survival of sickle RBCs. This study is registered at as NCT00040677.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sickle cell disease (SCD) is a very devastating condition caused by an autosomal recessive inherited haemoglobinopathy. This disease affects millions of peoples globally which results in serious complications due to vasoocclusive phenomenon and haemolysis. This genetic abnormality is due to substitution of amino acid valine for the glutamic acid at the sixth position of beta chain of haemoglobin. This disease was described about one hundred year ago. The haemoglobin S (hbS) produced as result of this defect is poorly soluble and polymerized when deoxygenated. Symptoms of sickle cell disease are due to chronic anaemia, pain full crises, acute chest syndrome, stroke and susceptibility to bacterial infection. In recent years measures like prenatal screening, better medical care, parent education, immunization and penicillin prophylaxis have successfully reduced morbidity and mortality and have increased tremendously life expectancy of affected individuals. Three principal current therapeutics modalities available for childhood SCD are blood transfusion, Hydroxy urea and bone marrow transplantation. Genetic counseling, continued medical education for health professionals about sickle cell disease, its complications and management is necessary. World health organization has actively promoted several national screening programms with dual goals of informing reproductive choice and thereby reducing the number of severely affected children.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal failure is a medical condition in which the kidneys are not working properly. There are two types of kidney failure: 1) acute kidney failure, which is sudden and often reversible with adequate treatment; and 2) chronic renal failure, which develops slowly and often is not reversible. The last stage of chronic renal failure is fatal without dialysis or kidney transplant. The treatment for chronic renal failure is focusing on slowing the progression of kidney damage. Several reports have described a promising approach to slow the loss of renal function through inhibition of the basolateral membrane, Ca2+-activated K+ (KCa3.1) channel with a selective and nontoxic blocker TRAM-34. This review summarizes pathophysiological studies that describe the role of KCa3.1 in kidney diseases.
    Frontiers in Biology. 12/2014; 10(1).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Idiopathic pulmonary fibrosis is a common and invariably fatal disease with limited therapeutic options. Ca2+-activated KCa3.1 potassium channels play a key role in promoting TGFß1 and bFGF-dependent profibrotic responses in human lung myofibroblasts (HLMFs). We hypothesised that KCa3.1 channel-dependent cell processes regulate HLMF ¿SMA expression via Smad2/3 signalling pathways.Methods In this study we have compared the phenotype of HLMFs derived from non-fibrotic healthy control lungs (NFC) with cells derived from IPF lungs. HLMFs grown in vitro were examined for ¿SMA expression by immunofluorescence (IF), RT-PCR and flow cytommetry. Basal Smad2/3 signalling was examined by RT-PCR, western blot and immunofluorescence. Two specific and distinct KCa3.1 blockers (TRAM-34 200 nM and ICA-17043 [Senicapoc] 100nM) were used to determine their effects on HLMF differentiation and the Smad2/3 signalling pathways.ResultsIPF-derived HLMFs demonstrated increased constitutive expression of both ¿-smooth muscle actin (¿SMA) and actin stress fibres, indicative of greater myofibroblast differentiation. This was associated with increased constitutive Smad2/3 mRNA and protein expression, and increased Smad2/3 nuclear localisation. The increased Smad2/3 nuclear localisation was inhibited by removing extracellular Ca2+ or blocking KCa3.1 ion channels with selective KCa3.1 blockers (TRAM-34, ICA-17043). This was accompanied by de-differentiation of IPF-derived HLMFs towards a quiescent fibroblast phenotype as demonstrated by reduced ¿SMA expression and reduced actin stress fibre formation.Conclusions Taken together, these data suggest that Ca2+- and KCa3.1-dependent processes facilitate ¿constitutive¿ Smad2/3 signalling in IPF-derived fibroblasts, and thus promote fibroblast to myofibroblast differentiation. Importantly, inhibiting KCa3.1 channels reverses this process. Targeting KCa3.1 may therefore provide a novel and effective approach for the treatment of IPF and there is the potential for the rapid translation of KCa3.1-directed therapy to the clinic.
    Respiratory Research 12/2014; 15(1):155. · 3.13 Impact Factor

Full-text (2 Sources)

Available from
May 22, 2014